The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2011Next Generation Parkinson's Disease Treatment through Steering Brain Stimulation (NEXT)
Objective/Rationale:
Deep Brain Stimulation (DBS) can provide a radical improvement in the quality of life of Parkinson’s patients. However, it is a complex procedure with a large incidence of... -
Therapeutics Development Initiative, 2011Characterization of NPT001-mediated Alpha-Synuclein Disaggregation and Clearance
Objective/Rationale:
Abnormal accumulation of alpha-synuclein in the brain is associated with toxicity and disease progression in Parkinson’s and other neurodegenerative diseases. NPT001 has been... -
LRRK2, 2011fMRI of First Degree Relatives of LRRK2 Positive Parkinson's Disease Patients
Objective/Rationale:
First, to study the effect of the presence of the LRRK2 G2019S mutation on brain activation patterns in PD patients who recently converted into a diseased state by comparing... -
LRRK2, 2011Increased Sensitivity to the Loss of Nigrostriatal Dopamine Following Progressive MPTP Treatment in LRRK2 Mutant Small Models
Objective/Rationale:
It is known that a mutation of specific gene, called LRRK2, increases the risks of developing Parkinson’s disease in humans. The specific objective of this proposal is to... -
Target Validation, 2011The Unfolded Protein Response (UPR) Chaperone GRP78/BiP as a Therapeutic Target for Alpha-Synuclein Toxicity
Objective/Rationale:
Glucose regulating protein 78 (GRP78/BiP), also known as BiP or HSPA5, is a member of the HSP70 family of chaperones. Along with its role in protein folding, GRP78/BiP is also... -
Target Validation, 2011Modulation of Microglial Activation
Objective/Rationale:
Over-activation of immune cells in the brain can lead to increased neuron loss in diseases such as Parkinson’s. Fractalkine is a protein that is a key player in controlling...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.